Delayed Severe Drug Induced Cholestasis After Anabolic Steroids Exposure by Alfarra, Rashed A et al.
Delayed Severe Drug Induced Cholestasis After Anabolic Steroids Exposure
Rashed A. Alfarra1 MD, Haris Hatic1 DO, Kelly M. Adkins2 MD, Shashi Poddar1 MD
1Graduate Medical Education in Internal Medicine, Gwinnett Medical Center, 1000 Medical Center Boulevard, 
Lawrenceville, Georgia 30046
2Gwinnett Pathology Associates, P.C., Gwinnett Medical center, 1000 Medical Center Boulevard, Lawrenceville, Georgia 
30046
Case report
Initial complete blood count and basic metabolic panel were 
unremarkable. Liver function profile with ALT of 44 IU/L, AST of 72 IU/L, 
Alk Phos of 266 IU/L, T. Bili of 21.4 mg/Dl, and INR of 1.2. The rest of his 
labs were unremarkable except for mildly elevated ferritin levels at 669 
ng/ML. 
Initial workup including hepatitis A, B and C, HSV 1&2, CMV, HIV, EBV, 
Wilson’s, hereditary hemochromatosis and autoimmune disorders were 
all negative. Imaging of the liver, gallbladder and the biliary system did 
not reveal any pathology (Figures 1, 2, and 3). Bilirubin was trended and 
continued to rise on the subsequent days, thus a CT-guided liver biopsy 
was performed. Slides were prepared and examined under the 
microscope using H&E stain and showed moderate to marked 
hepatocanalicular cholestasis with minimal centrilobular and 
hepatocellular injury (Figure 4, 5). 
•Figure 4. CT-guided core biopsy of liver shows 
moderate to marked hepatocanalicular cholestasis 
with centrizonal distribution and associated bile plugs 
(hematoxylin-eosin, original magnification 400X).
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That pathology finding in the light of the clinical presentation was 
strongly suggestive of drug induced cholestasis. The patient was 
discharged with cholestyramine and Zofran for symptomatic 
management. Follow up as an outpatient was scheduled with our 
resident clinic and bilirubin at discharge was 22.1 mg/dl. After two-
weeks, total bilirubin trended up to 39 mg/dl and the patient was 
started on ursodeoxycholic acid. At 4 weeks after discharge the 
total bilirubin started to decline to 13 mg/dl with resolution of his 
symptoms.
Introduction
A 20-year-old African American male without significant 
past medical history presented to the emergency 
department with jaundice, mild nausea, and generalized 
pruritis for four days. The patient stated that he had several 
episodes of non-bilious vomiting during this time. All his 
symptoms have been progressive and reports no prior 
incidence.
On social history, patient denied any illicit drug use or 
sexually transmitted infections but admitted to self-
initiation of oral stanozolol 40 mg daily. The patient used 
this anabolic steroid for 7 days 5 weeks prior to his 
symptoms developing. He denied any other prescription 
drug use or tobacco use. He admitted to occasional alcohol 
use that did not exceed 1-2 beers a week. 
Family history was negative for any liver disease 
including hepatitis, jaundice, cirrhosis, or malignancy.
Physical exam showed normal vital signs, mildly 
jaundiced well-nourished male with scleral icterus. His 
abdominal exam was benign without any 
hepatosplenomegaly; otherwise normal physical 
exam. 
References 
Anabolic steroids have become renowned as an 
enhancement tool for athletic performance and muscle 
development (1). One modification of testosterone is 
through alkylation of the C-17 position to allow for oral 
administration and that formula has been implicated in 
cases of certain liver injuries that are less common in 
esterified testosterones. These modified formulations 
include products such as danazol, methyltestosterone and 
stanazol (2). Testosterone therapy has been linked to 
distinctive form of acute cholestasis that generally arises 
within 1 to 4 months of therapy initiation but may be 
delayed to as long as 6 to 24 months (3). We are presenting 
a unique case where acute cholestasis occurred five weeks 
after discontinuation of Stanazol use of one-week. 
• The use of anabolic steroids has been linked to multiple liver 
pathologies including bland cholestasis, peliosis hepatis, hepatic 
adenoma, hepatocellular carcinoma and nodular regenerative 
hyperplasia. Most pathologies happen with long term use of 
these medications (4). However cholestasis can happen after a 
short course of anabolic steroids as seen in our case. 
• Oral anabolic steroids are more commonly associated with acute 
cholestasis due to the C-17 alkylation.
• Although cholestasis are usually reversable with stopping 
therapy, full recovery is often delayed. In addition, fatalities 
have been reported, usually due to marked cholestasis 
complicated by malnutrition, renal failure, and associated 
opportunistic infections (5).
• A study of men who regularly attended gyms in London in 2000 
found that 15.2% of the 792 men surveyed had used anabolic 
steroids in the preceding year (6). This data highlights the 
prevalence of anabolic steroids and the importance of asking 
about recent and remote anabolic steroids use in younger males 
with abnormal liver functions to prevent progressive liver injury. 
Hospital Course 
Figure 1, 2, and 3 
•Figure 5. CT-guided core biopsy of liver shows 
minimal hepatocellular injury with few perivenular 
hepatocytes with balloon degeneration and minimal 
to mild centrilobular inflammation (hematoxylin-
eosin, original magnification 400X).
